BACKGROUND: Promising new drugs such as lenalidomide, an immunomodulatory agent, are available for the treatment of multiple myeloma. We describe the process of creating a provincial guideline for the use of lenalidomide, alone or in combination with other drugs, in relapsed, refractory, or newly diagnosed disease (including smoldering and symptomatic patients, and candidates and non-candidates for transplant) and in maintenance treatment (after transplant or non-transplant therapy); and for strategies to manage lenalidomide-related toxicities. METHODS: Outcomes of interest included overall survival, event-free survival, progression-free survival, time to progression, time to next treatment, response rate, and incidence of serious toxicity. The medline, embase, and Cochrane Library databases, as well as meeting abstracts and the Web sites of relevant organizations, were systematically searched for relevant literature. RESULTS: Recommendations were developed using the evidence from published studies and the clinical expertise of the working group and of the Cancer Care Ontario Hematology Disease Site Group. CONCLUSIONS: Lenalidomide in combination with dexamethasone can be recommended for both previously untreated and treated patients with multiple myeloma. Guidelines for the management of cytopenias, venous thromboembolism, and second primary malignancies are discussed.
BACKGROUND: Promising new drugs such as lenalidomide, an immunomodulatory agent, are available for the treatment of multiple myeloma. We describe the process of creating a provincial guideline for the use of lenalidomide, alone or in combination with other drugs, in relapsed, refractory, or newly diagnosed disease (including smoldering and symptomatic patients, and candidates and non-candidates for transplant) and in maintenance treatment (after transplant or non-transplant therapy); and for strategies to manage lenalidomide-related toxicities. METHODS: Outcomes of interest included overall survival, event-free survival, progression-free survival, time to progression, time to next treatment, response rate, and incidence of serious toxicity. The medline, embase, and Cochrane Library databases, as well as meeting abstracts and the Web sites of relevant organizations, were systematically searched for relevant literature. RESULTS: Recommendations were developed using the evidence from published studies and the clinical expertise of the working group and of the Cancer Care Ontario Hematology Disease Site Group. CONCLUSIONS:Lenalidomide in combination with dexamethasone can be recommended for both previously untreated and treated patients with multiple myeloma. Guidelines for the management of cytopenias, venous thromboembolism, and second primary malignancies are discussed.
Entities:
Keywords:
Lenalidomide; imid; multiple myeloma; practice guideline
Authors: G P Browman; M N Levine; E A Mohide; R S Hayward; K I Pritchard; A Gafni; A Laupacis Journal: J Clin Oncol Date: 1995-02 Impact factor: 44.544
Authors: Meletios Dimopoulos; Adrian Alegre; Edward A Stadtmauer; Hartmut Goldschmidt; Jeffrey A Zonder; Carlos M de Castro; Zvenyslava Masliak; Donna Reece; Marta Olesnyckyj; Zhinuan Yu; Donna M Weber Journal: Cancer Date: 2010-08-15 Impact factor: 6.860
Authors: M A Dimopoulos; C Chen; A Spencer; R Niesvizky; M Attal; E A Stadtmauer; M T Petrucci; Z Yu; M Olesnyckyj; J B Zeldis; R D Knight; D M Weber Journal: Leukemia Date: 2009-07-23 Impact factor: 11.528
Authors: Michael Wang; Meletios A Dimopoulos; Christine Chen; M Teresa Cibeira; Michel Attal; Andrew Spencer; S Vincent Rajkumar; Zhinuan Yu; Marta Olesnyckyj; Jerome B Zeldis; Robert D Knight; Donna M Weber Journal: Blood Date: 2008-09-17 Impact factor: 22.113
Authors: S Vincent Rajkumar; Susanna Jacobus; Natalie S Callander; Rafael Fonseca; David H Vesole; Michael E Williams; Rafat Abonour; David S Siegel; Michael Katz; Philip R Greipp Journal: Lancet Oncol Date: 2009-10-21 Impact factor: 41.316
Authors: Maitreyee Hazarika; Edwin Rock; Gene Williams; Ramzi Dagher; Rajeshwari Sridhara; Brian Booth; Ann Farrell; Robert Justice; Richard Pazdur Journal: Oncologist Date: 2008-10-15
Authors: Philip L McCarthy; Kouros Owzar; Craig C Hofmeister; David D Hurd; Hani Hassoun; Paul G Richardson; Sergio Giralt; Edward A Stadtmauer; Daniel J Weisdorf; Ravi Vij; Jan S Moreb; Natalie Scott Callander; Koen Van Besien; Teresa Gentile; Luis Isola; Richard T Maziarz; Don A Gabriel; Asad Bashey; Heather Landau; Thomas Martin; Muzaffar H Qazilbash; Denise Levitan; Brian McClune; Robert Schlossman; Vera Hars; John Postiglione; Chen Jiang; Elizabeth Bennett; Susan Barry; Linda Bressler; Michael Kelly; Michele Seiler; Cara Rosenbaum; Parameswaran Hari; Marcelo C Pasquini; Mary M Horowitz; Thomas C Shea; Steven M Devine; Kenneth C Anderson; Charles Linker Journal: N Engl J Med Date: 2012-05-10 Impact factor: 91.245
Authors: Carmel Jacobs; Ian D Graham; Julie Makarski; Michaël Chassé; Dean Fergusson; Brian Hutton; Mark Clemons Journal: PLoS One Date: 2014-10-17 Impact factor: 3.240
Authors: Boris Decourt; Jeffrey Wilson; Aaron Ritter; Christopher Dardis; Frank P DiFilippo; Xiaowei Zhuang; Dietmar Cordes; Garam Lee; Nadia D Fulkerson; Tessa St Rose; Katurah Hartley; Marwan N Sabbagh Journal: Open Access J Clin Trials Date: 2020-01-07
Authors: Arif E Cetin; Mark M Stevens; Nicholas L Calistri; Mariateresa Fulciniti; Selim Olcum; Robert J Kimmerling; Nikhil C Munshi; Scott R Manalis Journal: Nat Commun Date: 2017-11-20 Impact factor: 14.919